



Ambu A/S – Capital Increase in connection with exercise of warrants issued

In April 2011, Ambu issued 440,000 warrants and in April 2012 507,600 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 2.50. 49 employees participate in the 2011 scheme, and 69 employees participate in the 2012 scheme. In both cases, the vesting period is three years, and both schemes can therefore be utilised in the trading window that opened on 6 May 2015 in connection with Ambu's interim report for Q2 2014/15.

Since 6 May 2015, instructions have been received to exercise warrants as follows:

- 2011 scheme: Four employees have issued instructions to exercise a total of 58,000 warrants at the agreed exercise price of DKK 40,125 and
- 2012 scheme: 39 employees have issued instructions to exercise a total of 299,600 warrants under the 2012 scheme at the agreed exercise price of DKK 39.50.

Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, Ambu's share capital will be increased by a nominal amount of DKK 894,000 from DKK 119,720,800 to DKK 120,614,800 through the issue of 357,600 Class B shares. The share capital is now divided into 41,381,920 Class B shares of DKK 2.50 each and 6,864,000 Class A shares of DKK 2.50 each.

Following this and in consideration of the employees having left the company, a total of 32,000 remaining warrants under the 2011 scheme are now being held by four individuals, while 146,000 remaining warrants under the 2012 scheme are now being held by 18 individuals.

The new Class B shares are expected to be admitted to trading and public listing on NASDAQ OMX Copenhagen A/S on 20 May 2015 under the ISIN code for Ambu A/S's existing Class B shares (DK0060591204).

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com
Ambu A/S
Baltorpbakken 13
DK-2750 Ballerup
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com

About Ambu

Since 1937, breakthrough ideas have driven our work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu bag and the legendary Blue Sensor® electrodes to our latest landmark solutions such as the aScope™ – the world's first single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medico-technical companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu has more than 2,350 employees in Europe, North America, Asia and the Pacific region. You can find more information about Ambu on our website: www.ambu.com.